epelsiban

Uses your system voice; voice and rate in settings.

Q5382095Snapshot

≈ 5 min read

Names in other languages

  • Englishepelsiban
  • Tiếng ViệtEpelsiban
  • 日本語エペルシバン

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Epelsiban ( , , code name GSK-557,296-B) is an orally bioavailable and peripherally selective drug which acts as a selective and potent oxytocin receptor antagonist (K i = 0.13 nM). It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF), and was also investigated for use in the treatment of adenomyosis.

Epelsiban ( , , code name GSK-557,296-B) is an orally bioavailable and peripherally selective drug which acts as a selective and potent oxytocin receptor antagonist (K i = 0.13 nM). It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF), and was also investigated for use in the treatment of adenomyosis. Screening the GSK compound collection and various libraries identified 2,5-diketopiperazines (2,5-DKPs) exemplified by 1 as novel and selective antagonists at the human oxytocin receptor (OTR). The lead, 1, showed potency of Ki = 300nM as a mixture of isomers in the amide side-chain. Initial structure–activity relationship (SAR) studies led to the semi-rigid and chirally pure 2,5-DKP 2 (Ki = 4nM), with cis disposed substituents at C-3 and C-6 and the R side-chain configuration at C-7. The optimal activity was shown to lie in the (3R, 6R, 7R) series (e.g., 2, 3) and an indanyl group was preferred at C-3, while at C-6, a 4-carbon branched alkyl was shown to be optimal. The (3R, 6R, 7R) series 2, 3 showed very good levels of selectivity relative to the vasopressin receptors. However, although all the (3R, 6R, 7R) isomers of the monosubstituted aryl 2,5-DKPs with wide range of different functionality had similarly high levels of potency, they all had low bioavailability in the rat. Optimization of the pharmacokinetic (PK) profile of this template was achieved by property-based design using an estimated of human oral absorption (EHOA) which focused the SAR on 2,5-DKPs with small exocyclic aromatic rings combined with small amides. This resulted in the 2’,4’-difluoro dimethylamide 3 which achieved good oral bioavailability in the rat (53%) and dog (51%) whilst retaining good oxytocin antagonist potency (Ki= 0.63nM) and >1000 fold selectivity relative to the human vasopressin V1A, V2, V1B receptors. The introduction of polar heterocycles to improve the solubility and human cytochrome P450 (Cyp450) enzyme profile of 3 using intrinsic clearance in microsomes to drive the improvements in the later’s pharmacokinetic profile lead to the 2’,6’-dimethyl-3’-pyridyl morpholine amide Epelsiban. In-vitro binding inhibition data showed that Epelsiban is a highly potent and selective non-peptide oxytocin antagonist with sub-namomolar potency at the human oxytocin receptor (hOTR) Ki = 0.13 nM and with>50000-fold, >63000-fold, and >31000-fold selectivity over the human V1a, V1b and V2 vasopressin receptors. It is also 100-fold more potent at the hOTR than atosiban (a marketed intravenous peptide oxytocin antagonist) and is 5-fold more potent against the hOTR, and more selective against the human vasopressin receptors, especially V2, than retosiban. High in vivo oxytocin antagonist potency was demonstrated in the anesthetized rat model, where uterine contractions were elicited by intravenous administration of oxytocin and reduction in uterine contractility was measured after subsequent intravenous administrations of increasing doses of Epelsiban, which gave an IC50 of 192nM.

Chemistry

Synthesis

The cyclic dipeptide Epelsiban is formed by cyclizing the corresponding linear dipeptide. In the highly stereoselective synthesis of Epelsiban 11, the linear peptide 8 is formed by the four-component Ugi reaction of the carboxybenzyl (Cbz) protected R-indanylglycine 4, D-alloisoleucine methyl ester hydrochloride 5, 2,6-dimethylpyridine-3-carboxaldehyde 6 and 2-benzyloxyphenylisonitrile 7. Hydrogenation to remove the Cbz and benzyl protecting groups, enabled cyclization of the linear peptide 8 to occur to give the phenolic cyclic dipeptide 9. Hydrolysis of the phenolic amide, by reaction with carbonyl diimidazole (CDI), followed by the addition of aqueous hydrochloric acid gave the acid 10 which was converted to the amide Epelsiban 11 by activating the acid with the peptide coupling reagent CDI, followed by the addition of morpholine. In this short lab-scale synthesis although the linear peptide 8 and the cyclic dipeptide 9 are a mixture of diastereoisomers (7RS) at the exocyclic amide, the hydrochloric acid hydrolysis of the activated phenolic amide caused epimerisation at the exocyclic position and yielded the acid 10 with the required (7R)-stereochemistry as the major product.

See also

Oxytocin receptor antagonist List of investigational sexual dysfunction drugs Atosiban Barusiban L-368,899 L-371,257 Retosiban

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1363460373 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.